Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
基本信息
- 批准号:10220588
- 负责人:
- 金额:$ 73.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdjuvantAdultAgingAgonistAntibody ResponseAntigensAntiviral ResponseAutomobile DrivingB-LymphocytesBiochemistryBioinformaticsBiological AssayBiologyBone MarrowCD4 Positive T LymphocytesCD8B1 geneCXCL10 geneCellsCellular ImmunityCellular ImmunologyClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCommunicable DiseasesDataDendritic CellsEngineered GeneEngineeringEnsureGenesGoalsHelminthsHelper-Inducer T-LymphocyteHumanImmuneImmune responseImmune signalingImmune systemImmunityImmunologicsImmunologyIndividualInfection preventionInterferonsInterleukin-10LeadLigandsMeasuresMemoryModelingMolecular ProfilingMorbidity - disease rateMusNatureOlder PopulationOnchocerca volvulusParasitesPathway interactionsPattern recognition receptorPeptidesProteinsReceptor CellRecording of previous eventsRegulatory PathwaySignal PathwaySignal TransductionSocietiesStimulator of Interferon GenesStructure of germinal center of lymph nodeT cell responseT-LymphocyteTLR7 geneTestingUp-RegulationVaccinationVaccinesage relatedagedaging populationasparaginasebasecell typeclinical efficacyhealthy aginghuman modelimmune activationimmunogenicityimmunosenescencein vivoinduced pluripotent stem cellinfluenza infectioninfluenza virus vaccineknockout genelymph nodesmicrobialmonocytemortalitymouse modelnovelnovel strategiespathogenrecruitresponsesynergismtranscriptomicsvaccine efficacyvaccinology
项目摘要
PROJECT ABSTRACT
Infectious diseases are a major cause of morbidity and mortality in the expanding older population. While
vaccines are efficient measures to prevent infections, a critical problem is that aging-associated changes in the
immune system lead to decreased immunogenicity and clinical efficacy of most currently used vaccines. Novel
strategies that increase vaccination efficacy and specifically target the aged immune system are imperative. An
essential facet of these efforts is the use of combinatory adjuvants that synergistically potentiate more effective
vaccine-induced immune responses against various pathogens. In this project we will define the mechanism of
action (MOA) of a combination of a unique parasite protein adjuvant, rASP-1 with each of three well-
characterized innate adjuvants: STING, TLR7/8 and RIG-I agonists, known to activate cytoplasmic pattern
recognition receptors and Type I IFN signaling, which are specifically dampened in the aged population. We
have shown that rASP-1 is a powerful adjuvant as it activates human and mouse dendritic cells to potentiate
the differentiation of naïve CD4+ T cells into Th1, Th17 and Tfh-like cells. Transcriptomic analyses of rASP-1-
activated hMoDCs revealed upregulation of the MyD88-independent activation pathway and interferon related
genes. In mice, rASP-1 elicits a balanced Th1/Th2 antibody response, Th1-biased cellular immunity, and
enhanced responses when co-administered with vaccines leading to increased survival following microbial
challenge. Importantly, our preliminary data indicate that rASP-1 in combination with 2’3’-cGAMP (STING),
R848 (TLR7/8) or 5’3p-hpRNA (RIG-I) in activated adult and aged mouse BMDCs can dramatically synergize
beyond merely additive effects; it enhanced secretion of IL-12p40, IP-10 and/or IL-10. The synergy is
exceptionally evident when it activates aged mouse BMDCs with the STING ligand. Therefore, we hypothesize
that combining rASP-1 with STING, TLR7/8 or RIG-I agonists will synergistically activate early innate immune
signaling that critically contributes to the establishment and nature of immune responses, and the duration and
intensity of immune activation. We posit that this will help restore the aging-associated deficits in the critical
regulatory pathways of the antiviral responses. Through comprehensive immunologic and transcriptomic
analyses, the MOA through which rASP-1 in combination with these three PRR agonists leads to optimal
activation of helper T cells driving humoral and cellular antiviral responses will be established in both mouse
(Aim 1) and human (Aim 2) DCs (adult and aged), to establish that they are conserved, and then test their
efficacy in vivo in adult and aged mice using the trivalent inactivated influenza vaccine (IIV3) as a model
antigen (Aim 3). This project brings together a dynamic team with a history of collaboration and complementary
expertise in vaccinology, immunology, biochemistry, innate cell receptor biology, adjuvants, and bioinformatics.
We will deliver a novel, efficacious combination of innate cytoplasmic PRR adjuvants with rASP-1 that
promotes protective long-lived adaptive responses and boosts efficacy of vaccines in aged populations.
项目摘要
在不断扩大的老年人口中,传染病是发病率和死亡率的主要原因。而当
疫苗是预防感染的有效措施,一个关键的问题是与衰老相关的变化
免疫系统导致目前使用的大多数疫苗的免疫原性和临床疗效降低。小说
提高疫苗接种效力并特别针对老年免疫系统的战略势在必行。一个
这些努力的基本方面是使用能够协同增强更有效的组合佐剂
疫苗诱导对各种病原体的免疫反应。在本项目中,我们将定义
一种独特的寄生虫蛋白佐剂rasp-1与三个孔-1的组合的作用(MOA)
固有佐剂:STING、TLR7/8和RIG-I激动剂,已知激活细胞质模式
识别受体和I型干扰素信号,这在老年人中特别受到抑制。我们
已经证明rasp-1是一种强大的佐剂,因为它激活了人和小鼠的树突状细胞,增强了
单纯CD4+T细胞向Th1、Th17和Tfh样细胞的分化Rasp-1-基因的转录转录分析
活化的hMoDC显示MyD88非依赖性激活途径上调和干扰素相关
基因。在小鼠中,rasp-1诱导平衡的Th1/Th2抗体反应,偏向Th1的细胞免疫,以及
与疫苗联合使用时的增强反应,导致微生物感染后的存活率增加
挑战。重要的是,我们的初步数据表明,rasp-1与2‘3’-cGAMP(STING)结合,
R848(TLR7/8)或5‘3P-hpRNA(RIG-I)在激活的成年和老年小鼠BMDCs中可以显著协同作用
除相加作用外,还可促进IL-12p40、IP-10和/或IL-10的分泌。协同效应是
当它用刺配体激活老化的小鼠骨髓细胞时,尤为明显。因此,我们假设
Rasp-1与STING、TLR7/8或RIG-I激动剂联合使用将协同激活早期先天免疫。
对免疫反应的建立和性质起关键作用的信号,以及持续时间和
免疫激活的强度。我们假设,这将有助于恢复与老龄化相关的赤字
抗病毒反应的调控途径。通过全面的免疫学和转录本
分析,rasp-1与这三种PRR激动剂联合使用的MOA导致最佳
将在两只小鼠中建立驱动体液和细胞抗病毒反应的辅助T细胞的激活
(目标1)和人类(目标2)DC(成人和老年),以确定它们是保守的,然后测试它们的
三价流感灭活疫苗(IIV3)对成年和老龄小鼠的体内免疫效果
抗原(目标3)。这个项目将一个充满活力的团队聚集在一起,具有合作和互补的历史
疫苗学、免疫学、生物化学、天然细胞受体生物学、佐剂和生物信息学方面的专业知识。
我们将提供一种新颖、有效的天然细胞质PRR佐剂与rasp-1的组合,
促进保护性长寿适应性反应,提高疫苗在老年人口中的效力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sara Lustigman其他文献
Sara Lustigman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sara Lustigman', 18)}}的其他基金
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10458553 - 财政年份:2021
- 资助金额:
$ 73.71万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10620718 - 财政年份:2021
- 资助金额:
$ 73.71万 - 项目类别:
Activating autophagy in filarial worms to identify novel macrofilaricides
激活丝虫中的自噬以鉴定新型大丝虫杀剂
- 批准号:
10198729 - 财政年份:2020
- 资助金额:
$ 73.71万 - 项目类别:
Activating autophagy in filarial worms to identify novel macrofilaricides
激活丝虫中的自噬以鉴定新型大丝虫杀剂
- 批准号:
10040523 - 财政年份:2020
- 资助金额:
$ 73.71万 - 项目类别:
The development of a recombinant vaccine against human onchocerciasis
人盘尾丝虫病重组疫苗的研制
- 批准号:
7919994 - 财政年份:2009
- 资助金额:
$ 73.71万 - 项目类别:
The development of a recombinant vaccine against human onchocerciasis
人盘尾丝虫病重组疫苗的研制
- 批准号:
9444432 - 财政年份:2009
- 资助金额:
$ 73.71万 - 项目类别:
The development of a recombinant vaccine against human onchocerciasis
人盘尾丝虫病重组疫苗的研制
- 批准号:
8512650 - 财政年份:2009
- 资助金额:
$ 73.71万 - 项目类别:
Malaria in Brazil: RBC variants & parasite invasion
巴西的疟疾:红细胞变异
- 批准号:
7913592 - 财政年份:2009
- 资助金额:
$ 73.71万 - 项目类别:
The development of a recombinant vaccine against human onchocerciasis
人盘尾丝虫病重组疫苗的研制
- 批准号:
7738645 - 财政年份:2009
- 资助金额:
$ 73.71万 - 项目类别:
The development of a recombinant vaccine against human onchocerciasis
人盘尾丝虫病重组疫苗的研制
- 批准号:
8099714 - 财政年份:2009
- 资助金额:
$ 73.71万 - 项目类别:
相似海外基金
Investigating HDAC3 phosphorylation as an epigenetic regulator of memory formation in the adult and aging brain
研究 HDAC3 磷酸化作为成人和衰老大脑记忆形成的表观遗传调节剂
- 批准号:
10752404 - 财政年份:2023
- 资助金额:
$ 73.71万 - 项目类别:
The Health of Aging Parents of Adult Children with Serious Conditions
患有严重疾病的成年子女的年迈父母的健康
- 批准号:
10660046 - 财政年份:2023
- 资助金额:
$ 73.71万 - 项目类别:
Understanding Longer-Living Older Adult Research: The Summer Program on Aging
了解长寿老年人研究:老龄化夏季项目
- 批准号:
476343 - 财政年份:2022
- 资助金额:
$ 73.71万 - 项目类别:
Role of sensory experience in the regulation of plasticity in the developing, adult and aging brain
感官体验在发育、成人和衰老大脑可塑性调节中的作用
- 批准号:
RGPIN-2019-04761 - 财政年份:2022
- 资助金额:
$ 73.71万 - 项目类别:
Discovery Grants Program - Individual
Adult Cognitive and Neurobiological Indicators of Aging: Impact of Adversity and Social Support
成人衰老的认知和神经生物学指标:逆境和社会支持的影响
- 批准号:
10365348 - 财政年份:2022
- 资助金额:
$ 73.71万 - 项目类别:
Adult Cognitive and Neurobiological Indicators of Aging: Impact of Adversity and Social Support
成人衰老的认知和神经生物学指标:逆境和社会支持的影响
- 批准号:
10700796 - 财政年份:2022
- 资助金额:
$ 73.71万 - 项目类别:
Endogenous barcoding to determine complex dynamics of adult neurogenesis in aging and Alzheimer's disease
内源条形码确定衰老和阿尔茨海默病中成人神经发生的复杂动态
- 批准号:
10651861 - 财政年份:2022
- 资助金额:
$ 73.71万 - 项目类别:
Investigating the interface of epigenetics and metabolism underlying memory formation in the adult, aging, and AD brain
研究成人、衰老和 AD 大脑中记忆形成的表观遗传学和代谢界面
- 批准号:
10420533 - 财政年份:2022
- 资助金额:
$ 73.71万 - 项目类别:
Endogenous barcoding to determine complex dynamics of adult neurogenesis in aging and Alzheimer's disease
内源条形码确定衰老和阿尔茨海默病中成人神经发生的复杂动态
- 批准号:
10846200 - 财政年份:2022
- 资助金额:
$ 73.71万 - 项目类别:
THE DEVELOPMENT OF MECHANISM-BASED ADULT STEM CELL TREATMENTS TO COMBAT AGING PATHOLOGIES
开发基于机制的成人干细胞疗法来对抗衰老病理学
- 批准号:
10721544 - 财政年份:2022
- 资助金额:
$ 73.71万 - 项目类别:














{{item.name}}会员




